MDCO: The Medicines Company - Summary | Jitta

The Medicines Company

NASDAQ:MDCO

Notice
Stock data is unavailable or the company’s delisted.
Price
$84.90
Loss Chance
58.4%
0.15JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (30)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Revenue and EarningEarning loss detected in 2018
Operating MarginInconsistent
Recent Business PerformanceEarning decline 47.54% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.15
100.00%
2.22
133.02%
3.06
156.15%
COMPANY DESCRIPTION
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey. As of January 3, 2020, The Medicines Company operates as a subsidiary of Novartis AG.